Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J
Department of Urology, School of Medicine, Chiba University, Japan.
Prostate. 1994 Jul;25(1):46-52. doi: 10.1002/pros.2990250107.
Thirty-two patients with voiding dysfunction attributable to symptomatic benign prostatic hyperplasia were treated with naftopidil, an alpha 1-blocker, at doses of 25-75 mg/day for 4-6 weeks. The efficacy of the drug was assessed from the changes in urinary symptoms and urodynamic data. Total symptom scores were significantly reduced after treatment (P < 0.001). Average flow rate and maximum flow rate were significantly increased (P < 0.001 and P < 0.001, respectively), and residual urine volume, residual urine rate (ratio of residual urine volume/sum of voided volume and residual urine volume), and maximum urethral closure pressure were significantly (P < 0.05, P < 0.01, and P < 0.05, respectively) reduced, and at bladder capacity, the first desire to void was significantly (P < 0.05) increased. The pressure/flow study demonstrated no changes in intravesical pressure at maximum flow, but a significant (P < 0.05) reduction in minimum urethral resistance. A mild side effect (dizziness) was noted in one patient (3.3%), which soon disappeared after the dose was decreased. The efficacy was good or excellent in 21 of 30 patients (70.0%). The drug was evaluated to be promising in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
32例因症状性良性前列腺增生导致排尿功能障碍的患者接受了萘哌地尔（一种α1阻滞剂）治疗，剂量为25 - 75毫克/天，疗程4 - 6周。通过排尿症状和尿动力学数据的变化评估药物疗效。治疗后总症状评分显著降低（P < 0.001）。平均尿流率和最大尿流率显著增加（分别为P < 0.001和P < 0.001），残余尿量、残余尿率（残余尿量/排尿量与残余尿量之和的比值）和最大尿道闭合压显著降低（分别为P < 0.05、P < 0.01和P < 0.05），在膀胱容量方面，首次排尿欲望显著增加（P < 0.05）。压力/流率研究表明，最大尿流时膀胱内压无变化，但最小尿道阻力显著降低（P < 0.05）。1例患者（3.3%）出现轻度副作用（头晕），剂量减少后很快消失。30例患者中有21例（70.0%）疗效良好或极佳。该药物在治疗良性前列腺增生引起的膀胱出口梗阻方面被评估为有前景。
